Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.48 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4901507 | 0.92 | HDAC1 (0.52) | ROCK2ROCK1SRCHDAC1HDAC8 | |
| SCHEMBL4897286 | 0.91 | MAOB (0.54) | ROCK2SRCHDAC1HDAC8HDAC6 | |
| SCHEMBL4889137 | 0.88 | HSD17B1 (0.52) | HDAC1HDAC8HDAC6HSD17B1HSD17B2 | |
| SCHEMBL4901490 | 0.86 | MAOB (0.53) | ROCK2ROCK1SRCHDAC1HDAC8 | |
| SCHEMBL4890398 | 0.83 | PDE4B (0.48) | HDAC1HDAC8HDAC6HSD17B1HSD17B2 | |
| SCHEMBL4894485 | 0.82 | DGAT2 (0.49) | HDAC1HDAC8HDAC6MAOB | |
| SCHEMBL4897133 | 0.82 | ROCK2 (0.42) | ROCK2ROCK1SRCHDAC1HDAC8 | |
| SCHEMBL4891848 | 0.82 | CDC7 (0.45) | ROCK2ROCK1SRC | |
| Hydrochloric Acid SCHEMBL28336261 | 0.80 | HDAC1 (0.55) | SRCHDAC1HDAC8HDAC6MAOB | |
| SCHEMBL12902828 | 0.79 | MAOB (0.48) | HDAC1HDAC8HDAC6MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815924-B2 | Heterocyclic carbonyl compounds | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | claimed |
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | claimed |
| US-8815924-B2 | Heterocyclic carbonyl compounds | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | SGK1, SGK2, SGK3 | ROCK2 1337/4885ROCK1 796/4885SRC 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.